SEC Form 4 · accession 0001209191-18-051833

Principia Biopharma Inc. · PRNB

Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗

Reporting owner

Director · 10% Owner

Period of report

Sep 18, 2018

Accepted (ET)

Sep 20, 2018 · 6:50 pm EDT

Rule 10b5-1 plan

unknown — predates the checkbox

Issuer CIK

0001510487

Table I — non-derivative securities

Security	Date	Code	Shares	Price	A/D	Owned after	D/I	Nature of ownership
Common Stock^F1,F2	Sep 18, 2018	C	1,070,771	—	A	1,070,771	I	See Footnote
Common Stock^F1,F2	Sep 18, 2018	C	312,741	—	A	1,383,512	I	See Footnote
Common Stock^F1,F2	Sep 18, 2018	C	260,617	—	A	1,644,129	I	See Footnote
Common Stock^F1,F2	Sep 18, 2018	C	544,047	—	A	2,188,176	I	See Footnote
Common Stock^F1,F2	Sep 18, 2018	C	167,537	—	A	2,355,713	I	See Footnote
Common Stock^F3,F2	Sep 18, 2018	P	270,000	$17.00	A	2,625,713	I	See Footnote

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Series A Preferred Stock^F1,F2	—	Sep 18, 2018	C	1,070,771	D	—	—	Common Stock	1,070,771	0	I
Series B-1 Preferred Stock^F1,F2	—	Sep 18, 2018	C	312,741	D	—	—	Common Stock	312,741	0	I
Series B-2 Preferred Stock^F1,F2	—	Sep 18, 2018	C	260,617	D	—	—	Common Stock	260,617	0	I
Series B-3 Preferred Stock^F1,F2	—	Sep 18, 2018	C	544,047	D	—	—	Common Stock	544,047	0	I
Series C Preferred Stock^F1,F2	—	Sep 18, 2018	C	167,537	D	—	—	Common Stock	167,537	0	I
Warrant (Right to Buy)^F2,F4,F5,F1	—	holding	—	—	—	—	—	Common Stock	28,623	28,623	I

F1The Series A, Series B-1, Series B-2, Series B-3 and Series C Preferred Stock were converted into Common Stock on a 9.0839-for-one basis upon the closing of the Issuer's initial public offering without payment of consideration. The Series A, Series B-1, Series B-2, Series B-3, and Series C Preferred Stock were convertible at any time at the holder's election and automatically upon the closing of the Issuer's initial public offering. The Preferred Stock had no expiration date.
F2S.R. One, Limited, an indirect, wholly-owned subsidiary of GlaxoSmithKline plc, is the record holder of the shares reported herein. Simeon J. George is a Partner and Vice President at S.R. One, Limited and an employee of GlaxoSmithKline LLC, a wholly-owned subsidiary of GlaxoSmithKline plc. Mr. George disclaims beneficial ownership of all the shares held by S.R. One, Limited and this report shall not be deemed an admission of beneficial ownership of such shares for the purposes of Section 16 or for any other purpose except to the extent of his pecuniary interest therein.
F3Reflects shares of the Issuer's Common Stock that were purchased in connection with the Issuer's initial public offering.
F4This warrant has converted from a warrant to purchase Series B-3 Preferred Stock into a warrant to purchase Common Stock.
F5The warrant is currently exercisable, with an expiration date of December 29, 2022, and an exercise price of $8.99 per share.